Division of Nephrology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, 130 Dongdeok-ro, Jung-gu, 41944, Daegu, South Korea.
Department of Pathology, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, 130 Dongdeok-ro, Jung-gu, 41944, Daegu, South Korea.
BMC Nephrol. 2024 Apr 5;25(1):123. doi: 10.1186/s12882-024-03524-y.
Primary focal segmental glomerulosclerosis (FSGS) is a glomerular disease that sometimes recurs in patients after kidney transplantation (KT) and increases the risk of graft loss. Proteinuria is a common early sign of recurrent FSGS, but an abrupt decrease in urine volume is rare. Herein, we report a patient with early recurrence of FSGS with anuria following KT.
A 55-year-old man with end-stage kidney disease caused by primary FSGS experienced anuria on postoperative day 2 following deceased donor KT. Laboratory results revealed that serum tacrolimus trough levels were consistently elevated at the time of anuria. At first, we considered acute calcineurin inhibitor (CNI) nephrotoxicity based on graft biopsy on light microscopy, laboratory findings, and clinical courses. However, the allograft function did not recover even after discontinuation of CNI, and recurrent FSGS was diagnosed 2 weeks later on electron microscopy. A total of 13 sessions of plasmapheresis and two administrations of rituximab (375 mg/m) were required to treat recurrent FSGS. The patient achieved a partial response, and the spot urine protein-to-creatinine ratio decreased from 15.5 g/g creatinine to 5.2 g/g creatinine. At 5 months following KT, the serum creatinine level was stable at 1.15 mg/dL.
These findings highlight that anuria can occur in cases of early recurrence of FSGS combined with acute CNI nephrotoxicity.
原发性局灶节段性肾小球硬化症(FSGS)是一种肾小球疾病,有时会在肾移植(KT)后复发,增加移植物丢失的风险。蛋白尿是 FSGS 复发的常见早期迹象,但尿量突然减少很少见。本文报告了一例 FSGS 早期复发伴 KT 后无尿的患者。
一名 55 岁男性,因原发性 FSGS 导致终末期肾病,在接受尸体供体 KT 后第 2 天出现无尿。实验室结果显示,无尿时血清他克莫司谷浓度持续升高。起初,我们根据光镜下的移植活检、实验室结果和临床过程考虑急性钙调神经磷酸酶抑制剂(CNI)肾毒性。然而,即使停用 CNI,移植物功能也未恢复,2 周后在电子显微镜下诊断为 FSGS 复发。总共需要 13 次血浆置换和 2 次利妥昔单抗(375mg/m)治疗 FSGS 复发。患者达到部分缓解,尿蛋白/肌酐比值从 15.5g/g 肌酐降至 5.2g/g 肌酐。在 KT 后 5 个月时,血清肌酐水平稳定在 1.15mg/dL。
这些发现强调了在 FSGS 早期复发合并急性 CNI 肾毒性的情况下可能发生无尿。